Trial · NCT00433381
Adverse events428
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 428
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Edema: limb: | Blood and lymphatic system disorders | Arm I (Bevacizumab and Temozolomide) | 16 | 60 | |
| other | Edema: limb: | Blood and lymphatic system disorders | Arm II (Bevacizumab and Irinotecan Hydrochloride) | 9 | 57 | |
| other | Epistaxis | Blood and lymphatic system disorders | Arm I (Bevacizumab and Temozolomide) | 14 | 60 | |
| other | Epistaxis | Blood and lymphatic system disorders | Arm II (Bevacizumab and Irinotecan Hydrochloride) | 10 | 57 | |
| other | Hemoglobin | Blood and lymphatic system disorders | Arm I (Bevacizumab and Temozolomide) | 26 | 60 | |
| other | Hemoglobin | Blood and lymphatic system disorders | Arm II (Bevacizumab and Irinotecan Hydrochloride) | 23 | 57 | |
| other | Hemorrhage/bleeding - Other: | Blood and lymphatic system disorders | Arm I (Bevacizumab and Temozolomide) | 3 | 60 | |
| other | Hemorrhage/bleeding - Other: | Blood and lymphatic system disorders | Arm II (Bevacizumab and Irinotecan Hydrochloride) | 0 | 57 | |
| other | Hemorrhagic stroke | Blood and lymphatic system disorders | Arm I (Bevacizumab and Temozolomide) | 3 | 60 | |
| other | Hemorrhagic stroke | Blood and lymphatic system disorders | Arm II (Bevacizumab and Irinotecan Hydrochloride) | 4 | 57 | |
| other | Leukopenia NOS | Blood and lymphatic system disorders | Arm I (Bevacizumab and Temozolomide) | 22 | 60 | |
| other | Leukopenia NOS | Blood and lymphatic system disorders | Arm II (Bevacizumab and Irinotecan Hydrochloride) | 21 | 57 | |
| other | Lower gastrointestinal hemorrhage | Blood and lymphatic system disorders | Arm I (Bevacizumab and Temozolomide) | 4 | 60 | |
| other | Lower gastrointestinal hemorrhage | Blood and lymphatic system disorders | Arm II (Bevacizumab and Irinotecan Hydrochloride) | 2 | 57 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Arm I (Bevacizumab and Temozolomide) | 29 | 60 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Arm II (Bevacizumab and Irinotecan Hydrochloride) | 30 | 57 | |
| other | Neutrophil count | Blood and lymphatic system disorders | Arm I (Bevacizumab and Temozolomide) | 9 | 60 | |
| other | Neutrophil count | Blood and lymphatic system disorders | Arm II (Bevacizumab and Irinotecan Hydrochloride) | 18 | 57 | |
| other | Platelet count decreased | Blood and lymphatic system disorders | Arm I (Bevacizumab and Temozolomide) | 30 | 60 | |
| other | Platelet count decreased | Blood and lymphatic system disorders | Arm II (Bevacizumab and Irinotecan Hydrochloride) | 20 | 57 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00433381/events